Business Context and Reporting Period
This Form 8-K was filed by VistaGen Therapeutics, Inc. on February 28, 2013, reporting events that occurred on February 22, 2013. The filing details an amendment to a Note Exchange and Purchase Agreement with Platinum Long Term Growth VII, LLC ("Platinum") regarding the issuance of senior secured promissory notes.
Key Financial Metrics and Transactions
- Debt Issuance: The Company issued an Investment Note with a principal amount of $250,000 to Platinum on February 22, 2013.
- Warrant Issuance: Concurrently, the Company issued a warrant to purchase 250,000 shares of common stock at an exercise price of $1.50 per share, exercisable over a five-year term.
- Remaining Obligation: Platinum is required to purchase a final Investment Note of $750,000 on or before March 12, 2013, unless otherwise agreed.
- Repayment Terms: The notes mature three years from issuance. Principal and accrued interest are payable via the issuance of restricted common stock, subject to conditions.
- Use of Proceeds: Proceeds are designated for general corporate purposes.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity positions.
Material Changes
The primary material change is the amendment to the October 11, 2012, Note Exchange and Purchase Agreement. This amendment modified the purchase schedule for the final $1.0 million tranche of notes, allowing Platinum to purchase the amount in two tranches rather than a single tranche due on February 22, 2013. The first tranche of $250,000 was executed on the reporting date.
Outlook, Risks, and Contingencies
- Future Obligation: The Company has a contingent obligation to issue a $750,000 note to Platinum by March 12, 2013.
- Dilution Risk: Repayment of the notes is structured as an issuance of restricted common stock, which will result in equity dilution upon maturity.
- Regulatory Status: The securities were sold under Section 4(2) of the Securities Act and Rule 506 of Regulation D to an accredited investor.
Key Facts for Investor Verification
- Verify the execution of the remaining $750,000 note purchase by Platinum on or before March 12, 2013.
- Review the specific conditions attached to the Investment Note that govern the conversion of principal and interest into restricted common stock.
- Assess the impact of the potential issuance of restricted shares on the Company's capital structure and existing shareholder dilution.
- Confirm the Company's cash position to ensure it can meet operational needs while awaiting the final tranche of funding.